Trending Topic

6 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Grace Johanna Salazar Tamayo

Highlights Determining infection and multidrug resistance (MDR) rates continuously helps to detect the problem to be solved, including outbreaks. Cleaning and disinfection play an important role in preventing MDR and evaluating and correcting the process for better results. MDR control can only be achieved with various measures applied continuously and consistently by a group of […]

Susan Swindells: Cabotegravir + Rilpivirine for the Treatment of HIV – FLARE and ATLAS Study Results

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 23rd 2021

It was a great pleasure to meet with Susan Swindells (University of Nebraska, Omaha, NE, USA) to discuss the FLAIR and ATLAS study results, following the recent FDA approval of cabotegravir + rilpivirine for the treatment of HIV-1.

Questions:

  1. What are the advantages of Cabenuva (cabotegravir + rilpivirine) compared to current treatment regimens?
  2. Could you give us a brief overview of the FLAIR and ATLAS studies?
  3. What did the findings of the FLAIR and ATLAS studies teach us about the efficacy of the treatment regimen?
  4. What were the study findings in terms of patient preference data?
  5. Which patients are most likely to benefit from this regimen and in whom is it contraindicated?

Disclosures: Susan Swindells’ institution has received research grants from ViiV Healthcare.

Support: Interview and filming supported by Touch Medical Media.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup